Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Avidian Wealth Enterprises LLC

Avidian Wealth Enterprises LLC boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 6.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,173 shares of the biopharmaceutical company’s stock after buying an additional 561 shares during the period. Avidian Wealth Enterprises LLC’s holdings in Gilead Sciences were worth $847,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Bellevue Group AG increased its stake in Gilead Sciences by 18.2% during the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock worth $3,859,000 after acquiring an additional 7,093 shares during the last quarter. Quantinno Capital Management LP boosted its holdings in Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock valued at $6,843,000 after purchasing an additional 48,910 shares during the period. McAdam LLC boosted its holdings in Gilead Sciences by 16.7% in the fourth quarter. McAdam LLC now owns 25,372 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 3,627 shares during the period. IRON Financial LLC purchased a new position in Gilead Sciences in the third quarter valued at $830,000. Finally, Capital Investment Advisors LLC lifted its holdings in Gilead Sciences by 2.6% during the 4th quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock worth $35,793,000 after buying an additional 9,791 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently commented on GILD. Wells Fargo & Company lifted their target price on Gilead Sciences from $105.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday. Robert W. Baird lifted their price objective on Gilead Sciences from $80.00 to $95.00 and gave the company a “neutral” rating in a report on Thursday, November 7th. Truist Financial lifted their price objective on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a report on Friday, November 8th. Daiwa America raised Gilead Sciences to a “hold” rating in a research note on Monday, November 18th. Finally, Wolfe Research started coverage on Gilead Sciences in a research note on Friday, November 15th. They issued an “outperform” rating and a $110.00 target price on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $101.04.

Insiders Place Their Bets

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the business’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $91.39, for a total transaction of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. The trade was a 43.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now owns 80,801 shares of the company’s stock, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 572,824 shares of company stock valued at $53,611,715. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Up 7.5 %

Shares of NASDAQ:GILD opened at $103.31 on Thursday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $104.71. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. The company has a market capitalization of $128.75 billion, a PE ratio of 1,147.89, a PEG ratio of 1.25 and a beta of 0.18. The company has a 50 day moving average price of $93.14 and a two-hundred day moving average price of $87.12.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. Analysts forecast that Gilead Sciences, Inc. will post 4.35 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 3.06%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is 3,422.22%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.